Hikma to deliver about 7% organic revenue growth for FY

Hikma Pharmaceuticals PLC announced that since the beginning of the year, the overall performance of the Group has been good and the Group remains on track to deliver around 7% organic revenue growth for the full year, with a gross margin of around 47%.

The company said that it is on track to deliver our forecast for the first half, in line with market expectations, driven by a recovery in Egypt and Tunisia and double-digit growth in most other markets. While sales activities in Libya and Yemen remain limited and in certain markets ACTOS sales have been suspended or negatively impacted by more restrictive labeling, the company continues to expect the Branded business to deliver around 7% revenue growth for the full year, with operating margins of around 23%.